Past 10 year's financial track record analysis by Moneyworks4me indicates that TGV SRACC Ltd is a average quality company.
The key valuation ratios of TGV SRACC Ltd's currently when compared to its past seem to suggest it is in the Fair zone.
The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of TGV SRACC Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.
| Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROCE % ⓘ | 12.9% | 11.9% | 12.5% | 16% | 21.6% | 12.6% | 9.6% | 21.5% | 38.7% | 8.2% | - |
| Value Creation Index ⓘ | -0.1 | -0.2 | -0.1 | 0.1 | 0.5 | -0.1 | -0.3 | 0.5 | 1.8 | -0.4 | - |
Growth Parameters ⓘGrowth Parameters Colour Code Guide ⓘ | |||||||||||
| Sales ⓘ | 777 | 816 | 931 | 1,189 | 1,205 | 1,040 | 1,009 | 1,525 | 2,326 | 1,546 | 1,577 |
| Sales YoY Gr. | - | 5.1% | 14.1% | 27.6% | 1.4% | -13.6% | -3% | 51.2% | 52.5% | -33.5% | - |
| Adj EPS ⓘ | 3.4 | 3.9 | 2.4 | 5.6 | 9.1 | 4.9 | 2.5 | 12.8 | 34.4 | 3 | 6.5 |
| YoY Gr. | - | 14.3% | -39.9% | 136.6% | 62.8% | -46.1% | -48% | 402.8% | 169.2% | -91.4% | - |
| BVPS (₹) ⓘ | 35.3 | 37.4 | 39.5 | 41.6 | 48.6 | 52.3 | 57 | 69.4 | 97.7 | 102.3 | 107 |
| Adj Net Profit ⓘ | 26.9 | 32.4 | 20.5 | 51.1 | 87.5 | 49.6 | 27.2 | 137 | 368 | 31.7 | 69 |
| Cash Flow from Ops. ⓘ | 65.3 | 50 | 142 | 153 | 202 | 122 | 132 | 168 | 429 | 164 | - |
| Debt/CF from Ops. ⓘ | 5 | 8.6 | 3.4 | 2.9 | 1.6 | 3.2 | 3.6 | 2.6 | 0.5 | 1.8 | - |
CAGR Colour Code Guide ⓘ
| 9 Years | 5 Years | 3 Years | 1 Years | |||||
|---|---|---|---|---|---|---|---|---|
| Sales ⓘ | 8% | 5.1% | 15.3% | -33.5% | ||||
| Adj EPS ⓘ | -1.6% | -20% | 5.2% | -91.4% | ||||
| BVPSⓘ | 12.5% | 16.1% | 21.6% | 4.7% | ||||
| Share Price | 22.5% | 37% | 29.1% | 2.5% | ||||
Performance Ratio Colour Code Guide ⓘ
| Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity % ⓘ | 9.4 | 10.2 | 6 | 14 | 20.3 | 9.8 | 4.7 | 20.2 | 41.1 | 3 | 6.2 |
| Op. Profit Mgn % ⓘ | 13.9 | 14.2 | 14.7 | 17 | 20.1 | 15.4 | 14.9 | 20.4 | 23.6 | 8.7 | 10.7 |
| Net Profit Mgn % ⓘ | 3.5 | 4 | 2.2 | 4.3 | 7.3 | 4.8 | 2.7 | 9 | 15.8 | 2.1 | 4.4 |
| Debt to Equity ⓘ | 1.1 | 1.3 | 1.4 | 1.2 | 0.7 | 0.7 | 0.8 | 0.6 | 0.2 | 0.3 | 0.1 |
| Working Cap Days ⓘ | 90 | 95 | 103 | 99 | 90 | 124 | 132 | 105 | 91 | 137 | 57 |
| Cash Conv. Cycle ⓘ | 9 | 15 | 16 | 22 | 27 | 49 | 51 | 45 | 42 | 66 | 5 |
Sales growth is growing at healthy rate in last 3 years 15.29%
Return on Equity has declined versus last 3 years average to 6.20%
Net Profit has been subdued in last 3 years 5.23%
Sales growth is not so good in last 4 quarters at -13.10%
| Standalone | Consolidated | |
|---|---|---|
| TTM EPS (₹) | 6.5 | - |
| TTM Sales (₹ Cr.) | 1,577 | - |
| BVPS (₹.) ⓘ | 107 | - |
| Reserves (₹ Cr.) ⓘ | 1,039 | - |
| P/BV ⓘ | 0.99 | - |
| PE ⓘ | 16.32 | - |
| From the Market | |
|---|---|
| 52 Week Low / High (₹) | 74.19 / 120.90 |
| All Time Low / High (₹) | 2.25 / 182.00 |
| Market Cap (₹ Cr.) | 1,130 |
| Equity (₹ Cr.) | 107.1 |
| Face Value (₹) | 10 |
| Industry PE ⓘ | 55.9 |
| Pledged * | 0.30 | 0.30 | 0.30 | 0.30 | 0.30 | 0.30 | 0.30 | 0.30 | 0.28 | 0.28 |
| PARTICULARS | Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 777 | 816 | 931 | 1,189 | 1,205 | 1,040 | 1,009 | 1,525 | 2,326 | 1,546 |
| Operating Expenses ⓘ | 669 | 704 | 794 | 987 | 964 | 883 | 859 | 1,219 | 1,786 | 1,412 |
| Manufacturing Costs | 314 | 338 | 383 | 471 | 565 | 479 | 407 | 670 | 979 | 732 |
| Material Costs | 286 | 282 | 305 | 266 | 262 | 279 | 336 | 396 | 564 | 452 |
| Employee Cost | 31 | 33 | 38 | 42 | 49 | 53 | 48 | 56 | 68 | 69 |
| Other Costs ⓘ | 37 | 49 | 69 | 209 | 88 | 72 | 68 | 98 | 176 | 158 |
| Operating Profit ⓘ | 108 | 113 | 137 | 201 | 241 | 157 | 150 | 306 | 539 | 134 |
| Operating Profit Margin (%) | 13.9% | 13.8% | 14.7% | 16.9% | 20.0% | 15.1% | 14.9% | 20.1% | 23.2% | 8.7% |
| Other Income ⓘ | 6 | 5 | 9 | 7 | 5 | 8 | 10 | 7 | 7 | 18 |
| Interest ⓘ | 40 | 44 | 60 | 58 | 71 | 44 | 48 | 35 | 30 | 25 |
| Depreciation ⓘ | 36 | 35 | 47 | 77 | 58 | 56 | 63 | 69 | 74 | 83 |
| Exceptional Items ⓘ | 0 | 0 | 0 | 0 | -12 | 0 | 0 | 0 | 0 | 40 |
| Profit Before Tax ⓘ | 37 | 39 | 40 | 73 | 105 | 65 | 49 | 209 | 442 | 84 |
| Tax ⓘ | 9 | 8 | 18 | 23 | 27 | 17 | 19 | 75 | 80 | 23 |
| Profit After Tax | 28 | 30 | 22 | 50 | 78 | 48 | 30 | 135 | 362 | 61 |
| PAT Margin (%) | 3.6% | 3.7% | 2.4% | 4.2% | 6.5% | 4.6% | 2.9% | 8.8% | 15.6% | 3.9% |
| Adjusted EPS (₹) | 3.6 | 3.6 | 2.5 | 5.5 | 8.1 | 4.7 | 2.8 | 12.6 | 33.8 | 5.7 |
| Dividend Payout Ratio (%) | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 18% |
| PARTICULARS | Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 |
|---|---|---|---|---|---|---|---|---|---|---|
Equity and Liabilities | ||||||||||
| Shareholders Fund | 297 | 328 | 345 | 382 | 469 | 532 | 610 | 744 | 1,047 | 1,096 |
| Share Capital ⓘ | 98 | 102 | 87 | 92 | 97 | 102 | 107 | 107 | 107 | 107 |
| Reserves ⓘ | 199 | 227 | 258 | 290 | 373 | 430 | 503 | 636 | 939 | 989 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Debt | 273 | 385 | 415 | 369 | 274 | 367 | 447 | 437 | 212 | 301 |
| Long Term Debt | 98 | 160 | 157 | 133 | 122 | 176 | 253 | 181 | 71 | 79 |
| Short Term Debt | 175 | 225 | 258 | 237 | 151 | 190 | 194 | 256 | 142 | 222 |
| Trade Payables | 56 | 65 | 82 | 59 | 48 | 55 | 74 | 72 | 65 | 48 |
| Others Liabilities ⓘ | 192 | 193 | 239 | 286 | 312 | 325 | 327 | 379 | 463 | 364 |
| Total Liabilities ⓘ | 818 | 972 | 1,081 | 1,096 | 1,103 | 1,279 | 1,459 | 1,632 | 1,786 | 1,808 |
Fixed Assets | ||||||||||
| Gross Block | 954 | 1,210 | 1,300 | 1,367 | 1,392 | 1,618 | 1,648 | 1,840 | 2,050 | 2,141 |
| Accumulated Depreciation | 509 | 550 | 601 | 698 | 757 | 811 | 874 | 938 | 1,009 | 1,093 |
| Net Fixed Assetsⓘ | 444 | 660 | 698 | 669 | 636 | 808 | 774 | 902 | 1,041 | 1,048 |
| CWIP ⓘ | 124 | 0 | 0 | 13 | 77 | 29 | 125 | 55 | 11 | 168 |
| Investmentsⓘ | 2 | 2 | 9 | 14 | 10 | 8 | 89 | 89 | 31 | 33 |
| Inventories | 43 | 70 | 66 | 65 | 90 | 127 | 116 | 109 | 140 | 126 |
| Trade Receivables | 53 | 65 | 75 | 106 | 99 | 83 | 99 | 232 | 227 | 188 |
| Cash Equivalents | 33 | 42 | 60 | 53 | 38 | 69 | 106 | 70 | 62 | 42 |
| Others Assetsⓘ | 119 | 133 | 172 | 176 | 153 | 155 | 149 | 174 | 274 | 202 |
| Total Assets ⓘ | 818 | 972 | 1,081 | 1,096 | 1,103 | 1,279 | 1,459 | 1,632 | 1,786 | 1,808 |
| PARTICULARS | Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash Flow From Operating Activity ⓘ | 65 | 50 | 142 | 153 | 202 | 122 | 132 | 168 | 429 | 164 |
| PBT ⓘ | 37 | 39 | 34 | 53 | 95 | 64 | 48 | 209 | 442 | 83 |
| Adjustment ⓘ | 66 | 70 | 97 | 145 | 117 | 91 | 94 | 89 | 98 | 101 |
| Changes in Working Capital ⓘ | -6 | -16 | 16 | -33 | 4 | -14 | 4 | -93 | -4 | -1 |
| Tax Paid ⓘ | -1 | -8 | -6 | -12 | -14 | -19 | -14 | -37 | -107 | -19 |
| Cash Flow From Investing Activity ⓘ | -52 | -132 | -109 | -75 | -55 | -188 | -163 | -147 | -169 | -223 |
| Capex | -52 | -132 | -90 | -81 | -89 | -157 | -125 | -126 | -169 | -244 |
| Net Investments | 0 | 0 | -23 | 0 | 30 | -35 | -43 | -27 | -5 | 14 |
| Others ⓘ | 0 | 0 | 4 | 6 | 4 | 4 | 4 | 6 | 5 | 7 |
| Cash Flow From Financing Activityⓘ | -2 | 91 | -33 | -76 | -145 | 65 | 58 | -38 | -255 | 49 |
| Net Proceeds from Shares ⓘ | 0 | 16 | 0 | 6 | 28 | 14 | 15 | 0 | 0 | 0 |
| Net Proceeds from Borrowing ⓘ | 0 | 0 | -18 | -6 | -10 | 53 | 77 | -73 | -111 | 9 |
| Interest Paid ⓘ | 0 | 0 | -50 | -51 | -62 | -36 | -36 | -27 | -23 | -23 |
| Dividend Paid ⓘ | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -11 |
| Others ⓘ | -2 | 75 | 35 | -25 | -101 | 34 | 2 | 62 | -122 | 75 |
| Net Cash Flow ⓘ | 11 | 9 | 0 | 2 | 2 | 0 | 26 | -18 | 5 | -9 |
| PARTICULARS | Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 |
|---|---|---|---|---|---|---|---|---|---|---|
| Ratios | ||||||||||
| ROE (%) | 10.56 | 10.28 | 6.7 | 13.84 | 18.38 | 9.6 | 5.21 | 19.88 | 40.45 | 5.69 |
| ROCE (%) | 12.87 | 11.85 | 12.47 | 15.99 | 21.61 | 12.56 | 9.57 | 21.53 | 38.65 | 8.2 |
| Asset Turnover Ratio | 1.09 | 1.03 | 1 | 1.12 | 1.28 | 0.87 | 0.74 | 0.99 | 1.36 | 0.86 |
| PAT to CFO Conversion(x) | 2.32 | 1.67 | 6.45 | 3.06 | 2.59 | 2.54 | 4.4 | 1.24 | 1.19 | 2.69 | Working Capital Days |
| Receivable Days | 22 | 23 | 25 | 27 | 27 | 32 | 33 | 40 | 36 | 49 |
| Inventory Days | 22 | 22 | 24 | 20 | 20 | 38 | 44 | 27 | 20 | 31 |
| Payable Days | 84 | 78 | 88 | 97 | 74 | 68 | 70 | 67 | 44 | 45 |
Sree Rayalaseema Alkalies & Allied Chemicals a TGV Group company is a leading producer of Chlor-Alkali products, Sree Rayalaseema Alkalies and Allied Chemicals is the flagship company of the conglomerate.
The company also manufactures Castor Derivatives and Fatty Acids. It has the unique distinction of being the pioneer of the Bipolar Membrane Cell Technology from Denora, Spa, Italy, in India. The company uses only state-of-the-art equipment and up-to-the minute technologies including the Costruzioni Meccaniche Bernardini (CMB) technology from Italy for its fatty acids division. A captive power plant assures uninterrupted and cost-effective power supply to the manufacturing plant. Consistent overseas demand for its products has made the company a recognised export house today.
TGV conglomerate is backed by a rich and varied experience spanning more than two glorious decades, is a rapidly growing, well-diversified one, with interests in Chemicals, Financial services, Merchant Banking, Securities, Real Estate, Power, Pharmaceuticals, Healthcare, Hospitality, Entertainment, Information Technology, Personal Products, Salt and Aquaculture.
The international class quality of the company's produce and the intricate marketing network spanning continents have found for it an assured place in the export markets ever since its inception. Canada, China, Dubai, France, Georgia, Germany, Greece, Iran, Italy, Japan, Jordan, Kenya, Korea, Kuwait, Malaysia, Netherlands, Poland, Russia, Singapore, Spain, Sri Lanka, Saudi Arabia, Thailand, USA, UK and a host of other countries prefer Sree Rayalaseema Alkalies and Allied Chemicals Ltd. over other players in the field. The soaps division exports its products to Sri Lanka, Malaysia, Kuwait, Sharjah, Bahrain, Dubai and other countries in the Gulf.
The soap division
The fragrant Royal Sandal Saffron Soap is the first and only one of its kind to bring the goodness of both saffron and sandal together and offer the 'fairness' benefit to the users.
Product range of the company includes:
Chlor-Alkali products:
Castor Derivatives:
Fatty Acids
Other group companies:
Achievements/ recognition:
The ISO 9002, ISO 14001 and IS-2888 certifications.
MoneyWorks4Me rating and ranking of funds for SIP is available to subscribers only. Moneyworks4Me is not a rating and ranking agency, however it is required that users have a way of selecting funds and building a Portfolio. The method used by it are described below to enable users to understand the logic behind the rating and ranking Subscriber will find more details on this in the various content made available from time to time. In case you need more please write to besafe@moneyworks4Me.com
MoneyWorks4Me rates and ranks mutual funds based on the following data-driven system:
Funds ranking in screeners: Performance Consistency and Quality are two parameters used for ranking funds for SIP. The ranking as follows GG, GO, GR, OG, OO, OR, RG, RO and RR.
With the same color-coded funds, the one with the higher Average 3-year rolling returns (over 5 to 10 years), the number that appears in the Performance tag, ranks higher.
Here is the summary:
The third tag Upside Potential is not relevant for SIP. It is relevant for lumpsum investments in Mutual Funds.
Make an informed decision for Stocks
Buy quality Stocks when they are available at reasonable prices and supported by an upward price trend and Sell when they are Overvalued using the Decizen Rating System. Covers 3500+ stocks
Download APP
